We are international
Donate
TEXT SIZE   


Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM

Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant.

12.05.15

video courtesy of http://share-at-congress.com


 related articles